Influence of noninjecting and injecting drug use on mortality, retention in the cohort, and antiretroviral therapy, in participants in the Swiss HIV Cohort Study

HIV Medicine

Volumn 16, Issue 3, 2015, Pages 137-151

  Weber, R ^a,i   Huber, M ^a   Battegay, M ^b,i   Stahelin C ^c   Castro Batanjer, E ^d   Calmy, A ^e,i   Bregenzer, A ^f   Bernasconi, E ^g,i   Schoeni Affolter, F ^h   Ledergerber, B ^a,i   Aubert, V ⁱ   Barth, J ⁱ   Boni J ⁱ   Bucher, H C ⁱ   Burton Jeangros, C ⁱ   Cavassini, M ⁱ   Egger, M ⁱ   Elzi, L ⁱ   Fehr, J ⁱ   Fellay, J ⁱ   Furrer, H ⁱ   Fux, C A ⁱ   Gorgievski, M ⁱ   Gunthard H ⁱ   Haerry, D ⁱ   Hasse, H ⁱ   Hirsch, H H ⁱ   Hosli I ⁱ   Kahlert, C ⁱ   Kaiser, L ⁱ   Keiser, O ⁱ   Klimkait, T ⁱ   Kovari, H ⁱ   Kouyos, R ⁱ   Martinetti, G ⁱ   Martinez de Tejada, B ⁱ   Metzner, K ⁱ   Muller N ⁱ   Nadal, D ⁱ   Pantaleo, G ⁱ   Rauch, A ⁱ   Regenass, S ⁱ   Rickenbach, M ⁱ   Rudin, C ⁱ   Schmid, P ⁱ   Schultze, D ⁱ   Schoni Affolter F ⁱ   Schupbach J ⁱ   Speck, R ⁱ   Staehelin, C ⁱ   Tarr, P ⁱ   Telenti, A ⁱ   Trkola, A ⁱ   Vernazza, P ⁱ   Yerly, S ⁱ   more..

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^g REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^h UNIVERSITY OF LAUSANNE   (Switzerland)

ⁱ NONE

Author keywords

Alcohol use; Antiretroviral therapy; Cohort study; HIV infection; Injecting drug use; Noninjecting drug use; Opiate substitution; Smoking

Indexed keywords

4 HYDROXYBUTYRIC ACID; AMPHETAMINE DERIVATIVE; ANTIRETROVIRUS AGENT; ANXIOLYTIC AGENT; CANNABIS; COCAINE; DIAMORPHINE; HYPNOTIC AGENT; OPIATE; SEDATIVE AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS RNA;

ADOLESCENT; ADULT; ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; DRUG TREATMENT FAILURE; DRUG USE; FEMALE; FOLLOW UP; HETEROSEXUALITY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTING DRUG USE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONINJECTING DRUG USE; PRIORITY JOURNAL; QUESTIONNAIRE; SELF REPORT; SWISS; VIRUS REPLICATION; VIRUS TRANSMISSION; CD4 LYMPHOCYTE COUNT; CLINICAL PRACTICE; CLINICAL TRIAL; COMPLICATION; HIV INFECTIONS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MEDICATION COMPLIANCE; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; PSYCHOLOGY; RISK; RISK FACTOR; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE; SUBSTANCE-RELATED DISORDERS; SWITZERLAND; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG USERS; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; LOST TO FOLLOW-UP; MEDICATION ADHERENCE; MIDDLE AGED; ODDS RATIO; PHYSICIAN'S PRACTICE PATTERNS; PROSPECTIVE STUDIES; RISK FACTORS; RNA, VIRAL; SUBSTANCE ABUSE, INTRAVENOUS; SUBSTANCE-RELATED DISORDERS; SWITZERLAND; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84922789396     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12184     Document Type: Article

References (53)

1. Milloy MJ, Marshall BD, Kerr T etal. Social and structural factors associated with HIV disease progression among illicit drug users: a systematic review. AIDS 2012; 26: 1049-1063.
2. Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 2012; 379: 55-70.
3. The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA 2013; 310: 591-608.
4. The United Nations Office on Drugs and Crime: World Drug Report 2013. United Nations publication, Sales No. E.13.XI.6, Vienna, 2013.
5. Conen A, Fehr J, Glass TR etal. Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study. Antivir Ther 2009; 14: 349-357.
6. Conen A, Wang Q, Glass TR etal. Association of alcohol consumption and HIV surrogate markers in participants of the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2013; 64: 472-478.
7. Kipp AM, Desruisseau AJ, Qian HZ. Non-injection drug use and HIV disease progression in the era of combination antiretroviral therapy. J Subst Abuse Treat 2011; 40: 386-396.
8. Peterson PK, Sharp BM, Gekker G, Portoghese PS, Sannerud K, Balfour HH, Jr. Morphine promotes the growth of HIV-1 in human peripheral blood mononuclear cell cocultures. AIDS 1990; 4: 869-873.
9. Peterson PK, Gekker G, Chao CC, Schut R, Molitor TW, Balfour HH, Jr. Cocaine potentiates HIV-1 replication in human peripheral blood mononuclear cell cocultures. Involvement of transforming growth factor-beta. J Immunol 1991; 146: 81-84.
10. Donahoe RM, Byrd LD, McClure HM etal. Consequences of opiate-dependency in a monkey model of AIDS. Adv Exp Med Biol 1993; 335: 21-28.
11. Cabral GA, Dove Pettit DA. Drugs and immunity: cannabinoids and their role in decreased resistance to infectious disease. J Neuroimmunol 1998; 83: 116-123.
12. Klein TW, Friedman H, Specter S. Marijuana, immunity and infection. J Neuroimmunol 1998; 83: 102-115.
13. Cabral GA. Drugs of abuse, immune modulation, and AIDS. J Neuroimmune Pharmacol 2006; 1: 280-295.
14. Dronda F, Zamora J, Moreno S etal. CD4 cell recovery during successful antiretroviral therapy in naive HIV-infected patients: the role of intravenous drug use. AIDS 2004; 18: 2210-2212.
15. Disease progression and early predictors of AIDS in HIV-seroconverted injecting drug users. The Italian Seroconversion Study. AIDS 1992; 6: 421-426.
16. Pezzotti P, Galai N, Vlahov D, Rezza G, Lyles CM, Astemborski J. Direct comparison of time to AIDS and infectious disease death between HIV seroconverter injection drug users in Italy and the United States: results from the ALIVE and ISS studies. AIDS Link to Intravenous Experiences. Italian Seroconversion Study. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20: 275-282.
17. Prins M, Veugelers PJ. Comparison of progression and non-progression in injecting drug users and homosexual men with documented dates of HIV-1 seroconversion. European Seroconverter Study and the Tricontinental Seroconverter Study. AIDS 1997; 11: 621-631.
18. Baum MK, Rafie C, Lai S, Sales S, Page B, Campa A. Crack-cocaine use accelerates HIV disease progression in a cohort of HIV-positive drug users. J Acquir Immune Defic Syndr 2009; 50: 93-99.
19. Bassetti S, Battegay M, Furrer H etal. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 1999; 21: 114-119.
20. Schoeni-Affolter F, Ledergerber B, Rickenbach M etal. Cohort profile: the Swiss HIV Cohort study. Int J Epidemiol 2010; 39: 1179-1189.
21. Glass TR, De Geest S, Hirschel B etal. Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients. Antivir Ther 2008; 13: 77-85.
22. Kowalska JD, Friis-Moller N, Kirk O etal. The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology. Epidemiology 2011; 22: 516-523.
23. Weber R, Ruppik M, Rickenbach M etal. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med 2013; 14: 195-207.
24. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Statist Assoc 1999; 94: 496-509.
25. Lucas GM, Griswold M, Gebo KA, Keruly J, Chaisson RE, Moore RD. Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. Am J Epidemiol 2006; 163: 412-420.
26. Ickovics JR, Hamburger ME, Vlahov D etal. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA 2001; 285: 1466-1474.
27. Cohen MH, French AL, Benning L etal. Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. Am J Med 2002; 113: 91-98.
28. Anastos K, Schneider MF, Gange SJ etal. The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. J Acquir Immune Defic Syndr 2005; 39: 537-544.
29. Cook JA, Grey D, Burke J etal. Depressive symptoms and AIDS-related mortality among a multisite cohort of HIV-positive women. Am J Public Health 2004; 94: 1133-1140.
30. Kapadia F, Vlahov D, Donahoe RM, Friedland G. The role of substance abuse in HIV disease progression: reconciling differences from laboratory and epidemiologic investigations. Clin Infect Dis 2005; 41: 1027-1034.
31. Cook JA, Burke-Miller JK, Cohen MH etal. Crack cocaine, disease progression, and mortality in a multicenter cohort of HIV-1 positive women. AIDS 2008; 22: 1355-1363.
32. Thorpe LE, Frederick M, Pitt J etal. Effect of hard-drug use on CD4 cell percentage, HIV RNA level, and progression to AIDS-defining class C events among HIV-infected women. J Acquir Immune Defic Syndr 2004; 37: 1423-1430.
33. Hershow RC, O'Driscoll PT, Handelsman E etal. Hepatitis C virus coinfection and HIV load, CD4+ cell percentage, and clinical progression to AIDS or death among HIV-infected women: Women and Infants Transmission Study. Clin Infect Dis 2005; 40: 859-867.
34. Chao C, Jacobson LP, Tashkin D etal. Recreational drug use and T lymphocyte subpopulations in HIV-uninfected and HIV-infected men. Drug Alcohol Depend 2008; 94: 165-171.
35. Chao C, Jacobson LP, Jenkins FJ etal. Recreational drug use and risk of Kaposi's sarcoma in HIV- and HHV-8-coinfected homosexual men. AIDS Res Hum Retroviruses 2009; 25: 149-156.
36. Chao C, Jacobson LP, Tashkin D etal. Recreational amphetamine use and risk of HIV-related non-Hodgkin lymphoma. Cancer Causes Control 2009; 20: 509-516.
37. Des Jarlais DC, Friedman SR, Marmor M etal. Development of AIDS, HIV seroconversion, and potential co-factors for T4 cell loss in a cohort of intravenous drug users. AIDS 1987; 1: 105-111.
38. Chaisson RE, Keruly JC, Moore RD. Race, sex, drug use, and progression of human immunodeficiency virus disease. N Engl J Med 1995; 333: 751-756.
39. Weber R, Ledergerber B, Opravil M, Siegenthaler W, Luthy R. Progression of HIV infection in misusers of injected drugs who stop injecting or follow a programme of maintenance treatment with methadone. BMJ 1990; 301: 1362-1365.
40. Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr 2001; 27: 251-259.
41. Perez-Hoyos S, Ferreros I, del Amo J etal. Survival and progression to AIDS in a seroconverter cohort in the post-highly active antiretroviral therapy era: effectiveness goes on. AIDS 2006; 20: 289-291.
42. May M, Sterne JA, Sabin C etal. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007; 21: 1185-1197.
43. Zwahlen M, Harris R, May M etal. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol 2009; 38: 1624-1633.
44. Weber R, Huber M, Rickenbach M etal. Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study. HIV Med 2009; 10: 407-416.
45. Shirley DK, Kaner RJ, Glesby MJ. Effects of smoking on non-AIDS-related morbidity in HIV-infected patients. Clin Infect Dis 2013; 57: 275-282.
46. Kaufman JS, Maclehose RF, Kaufman S. A further critique of the analytic strategy of adjusting for covariates to identify biologic mediation. Epidemiol Perspect Innov 2004; 1: 4.
47. Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology 2009; 20: 488-495.
48. Spoerri A, Zwahlen M, Egger M, Bopp M. The Swiss National Cohort: a unique database for national and international researchers. Int J Public Health 2010; 55: 239-242.
49. The Swiss Federal Statistical Office. Mortality, causes of death: data, indicators. Available at http://www.bfs.admin.ch/bfs/portal/en/index/themen/14/02/04/key/01.html (accessed 11 August 2013).
50. Latkin CA, Vlahov D, Anthony JC. Socially desirable responding and self-reported HIV infection risk behaviors among intravenous drug users. Addiction 1993; 88: 517-526.
51. Wilcox CE, Bogenschutz MP, Nakazawa M, Woody G. Concordance between self-report and urine drug screen data in adolescent opioid dependent clinical trial participants. Addict Behav 2013; 38: 2568-2574.
52. Bale RN, van Stone WW, Engelsing TM, Zarcone VP, Jr, Kuldan JM. The validity of self-reported heroin use. Int J Addict 1981; 16: 1387-1398.
53. Denis C, Fatseas M, Beltran V etal. Validity of the self-reported drug use section of the Addiction Severity Index and associated factors used under naturalistic conditions. Subst Use Misuse 2012; 47: 356-363.